Boundless Bio, Inc.

NasdaqGS:BOLD

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 23.95 M

Share Price

USD 1.07

Avg Daily Volume

74,090

Change (1 day)

0.00%

Change (1 year)

Change (YTD)

-51.80%

Boundless Bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025

Boundless Bio, Inc. Free Cash Flow is NA for the Trailing 12 Months (TTM) ending March 31, 2025. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Boundless Bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -51.17 M.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

NasdaqGS: BOLD

Boundless Bio, Inc.

CEO	Mr. Zachary Hornby
IPO Date	July 20, 2016
Location	United States
Headquarters	9880 Campus Point Drive
Employees	64
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.